{"name":"Opus Genetics, Inc","slug":"opus-genetics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":5476776,"netIncome":-49591000,"cash":45091000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AAV8.hLCA5","genericName":"AAV8.hLCA5","slug":"aav8-hlca5","indication":"Leber congenital amaurosis 10 (LCA10)","status":"phase_1"}]}],"pipeline":[{"name":"AAV8.hLCA5","genericName":"AAV8.hLCA5","slug":"aav8-hlca5","phase":"phase_1","mechanism":"Gene therapy for Leber congenital amaurosis 10 (LCA10)","indications":["Leber congenital amaurosis 10 (LCA10)"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1XaHBmTDdGandMWC1vN1kxUUdjZnpIS1hodnFwTXVjSzFVYWM4dXE0XzlRdms5Yi13UWRoTGVLWWNGME9MSmVWMmdIMElIWUlmVy1XQ0dtZXI1RXdPTmp0YkRBVG5aQQ?oc=5","date":"2026-03-21","type":"pipeline","source":"Stock Titan","summary":"OCUP SEC Filings - Ocuphire Pharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan","headline":"OCUP SEC Filings - Ocuphire Pharma Inc 10-K, 10-Q, 8-K Forms","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNcThoY21qbjNndEZQeGpuTEZOeGl1N3BLYWVSUFoyTWUtYXVRQkRlY1R5RUNwMjJ2eHVjX1hUUUp1NUxPWVg0NldLVWtFUDcwaV9IaHRWMXlWd2NGRUdoejhOYjN5NEx2Tkc0cnhOeHFta0NCV3B2R3lBV3c5bFQ3cnBOZWZSMVpNTk9ZV0FHR0R5R1QxZkJIMmFnR2d6SnhkSlBNUmg1bw?oc=5","date":"2026-03-04","type":"pipeline","source":"The Business Journals","summary":"RTP firm looks to expand market for eye-drop treatment - The Business Journals","headline":"RTP firm looks to expand market for eye-drop treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPbnhCOTNpV2dSQ0d5NmVyQ2lDdGJ0WV91SDdyd1pwcURBTm1jdzFNcWJfejhOeEtDQzZJN3VZeTBzMWpfc0FsYk9vWmlfOVRZY1d2dHNnYXp1a092eVBqbTNXX2pobzQzdmVxOHBqcFVrMkhlbUxkZV9VaWV2QWlDSXJKOU44WW0tbTRjcGdRNnBPc202bWlLbUhUSFgtaTZSeGNhZmZkNWI?oc=5","date":"2026-02-25","type":"regulatory","source":"Eyes On Eyecare","summary":"FDA accepts sNDA of phentolamine 0.75% for presbyopia - Eyes On Eyecare","headline":"FDA accepts sNDA of phentolamine 0.75% for presbyopia","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQcnQwUEpuNVh2T2F1VjlYM01lazE3bnBiZ0w2aUY4a2dRa3hQQmtPRlY3VXQ1eTJlQktYd01jZWN5LXE3dm53NjloYUxwVk01cEJxemhEdUxnV2RFUXMxSE9hT3lERUFiUm9kZW1vN1hDcGw4U2E4eW9DRkFYSWRJdm1pUVhuLThvM25ndUtnT0o?oc=5","date":"2025-12-09","type":"trial","source":"Seeking Alpha","summary":"Opus Genetics rises on update from eye disease study (IRD) - Seeking Alpha","headline":"Opus Genetics rises on update from eye disease study (IRD)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-19","type":"pipeline","source":"simplywall.st","summary":"Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results - simplywall.st","headline":"Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNWk9xSnlRRFBWd0NKNXNGZ1VtU2szcDVCUGIwSEpfNnl2MElCRWRhZ1dNUlNEbWdKc2FpdFN6STV3aUg4Smx2eEFoZzdpd1pLSjNsOFNua0p3c0dzMHg4V0Nod0ktelFLS2hwTmU0elp5NjIyVzUzc0NDbHhfazBzcEtMcWxzXzJUUmxSLWxoWk83QlhpZ3c?oc=5","date":"2025-04-11","type":"pipeline","source":"Crain's Detroit","summary":"Drug company founder pulls plug on proxy fight at her former company - Crain's Detroit","headline":"Drug company founder pulls plug on proxy fight at her former company - Crain's Detroit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQaFdwb0t1NlhNcW40ZnpENlYyRjJuVXA4aUNkWFBKRlJkQXJ4NzBsenBJVUpXVUdzWnJZRUc1TlVWRTJGekVHb0xUZHo2N0JKZDZNUFpTWjJhNmdVQTBVWEh6aEdlVEJGdVFhSjZxS1lKU0NLelg5bk5xSzN4NEJyalBVcmwyaDM3aUltTUJRTEQzekRVelJtOHcyZHpmLVlfaW1ZTGNXX0s5OHViem5NNjlKMUJiUFdVVGllQWt0X2taaG0z?oc=5","date":"2025-03-20","type":"patent","source":"Investing.com","summary":"Opus Genetics enhances shareholder rights, sues for patent infringement - Investing.com","headline":"Opus Genetics enhances shareholder rights, sues for patent infringement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxORDNGWG1JWFFxYUVLUmRHN09Ndm5ra2JFQXRxSVdveFdfZGFvMnc3bXBkczhBbHIzWjU0OVcwazk2cFdjUm9pR3B6WWxPVnNZWi1hWjR4TEtVeVNwNVZESHV6am82eTcwaWRaVVkxVkhWSmhjUk1qZS1WMk5IUERVbkpBWjVrN243WHBiZ0k0SXZuNFdhWllUV0dLSmgtTHhIZXNJbXNGbjdmOFRvMzV4em1Zel9lejN1OWZEZGtCOXM?oc=5","date":"2024-10-25","type":"pipeline","source":"PR Newswire","summary":"The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - PR Newswire","headline":"The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxONlBUZWswaHZ4S1UtWGQxdi1hQXZKU2xXSzc3OXRSR0EtOEdEel9CdGdsZ0V5VFlERXVnNEozcVZlM2FfNW9KbDN2Nm9VcHF4MDdkMGdaWHJ3WDFsT3NpelVnRGV2d196VXp1X2NyX2szYkhybVFxY092OWp3bkJUYWM4OWpJcVBLamc?oc=5","date":"2024-10-23","type":"pipeline","source":"Yahoo Finance","summary":"Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics - Yahoo Finance","headline":"Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPZERndFpCSExmMUhjMUREWkZoMW11TU9RdUVlRkxSdFJ0SXVmbmRTbnBfSWFQQmRra3VpWGdfR2lOdkY0SzFyRnB5R2ZxTzdRYVJCWm9QNDVhdUtBaU5wcDFaX2JiVEg5bExaRkJSNW50M1poVTFOTWRid3JXSDJsdXdtS3hCQVVUMWNqQ0FjUjJHcTJFOVc4YWJyYUNSdGx0UkJLLQ?oc=5","date":"2024-10-23","type":"pipeline","source":"Fierce Biotech","summary":"Ocuphire Pharma to transform into gene-therapy-focused biotech via Opus acquisition - Fierce Biotech","headline":"Ocuphire Pharma to transform into gene-therapy-focused biotech via Opus acquisition","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":0,"revenuePeriod":"2013-12-31","revenueHistory":[{"value":0,"period":"2013-12-31"},{"value":0,"period":"2012-12-31"},{"value":0,"period":"2011-12-31"},{"value":0,"period":"2010-12-31"},{"value":0,"period":"2009-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":5476776,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-49591000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":45091000,"cashHistory":[],"totalAssets":50243000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}